Nasdaq
$12.83▲ 0.23%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $457.6MShares out 35.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.15After-hours26.10.16 05:268-KKey event#●●●#●●●#●●●
CRESCENT BIOPHARMA, INC.
Crescent Biopharma is advancing its Phase 1/2 ASCEND trial for CR-001, with initial monotherapy data expected in Q1 2027 and combination therapy data in mid-2027. The company also received FDA clearance for its PD-L1 targeting ADC, CR-002, and plans to initiate the Phase 1/2 APOLLO trial in Q4 2026 while expanding its ADC pipeline through a partnership with Kelun-Biotech.…more
$12.83+0.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18After-hours26.09.19 05:034Ownership
CRESCENT BIOPHARMA, INC.
Insider Lynch Ryan reported a change in beneficial ownership of securities for Crescent Biopharma, Inc. as of September 16, 2026. This filing serves as an official notification of the insider's equity transaction to the SEC.…more
$12.83+0.23%vs prev closeView filingShare - 9.18After-hours26.09.19 05:034Ownership
CRESCENT BIOPHARMA, INC.
Insider Jan Pinkas of Crescent Biopharma, Inc. filed a Form 4 on September 18, 2026, reporting a change in beneficial ownership of securities as of September 16, 2026. This filing serves as the official record of the insider's transaction.…more
$12.83+0.23%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15After-hours26.10.16 05:31#●●●#●●●#●●●
Crescent Biopharma Provides Updates on ADC Clinical Trials
Crescent Biopharma is on track to begin dosing for its PD-L1-targeted ADC, CR-002, this quarter, with initial data expected in late 2027. Additionally, the company continues its Phase 1/2 trial for the ITGB6-targeted ADC, CR-003, in China, with data anticipated in the first quarter of 2027.…more
$12.83+0.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15After-hours26.10.16 05:15
●●●●●●●● ●●●●● ●●●●●●
Crescent Biopharma is advancing its clinical pipeline, including patient enrollment for the Phase 1/2 trial of its lead candidate, CR-001. While the company expects to report initial clinical data starting in 2027, it remains in the early clinical development stage.…more
$12.83+0.23%vs prev close - 10.6After-hours26.10.07 05:15
●●●●●●●● ●●●●● ●●●●●●
Crescent Biopharma has granted stock options for a total of 81,525 shares to six new employees as an equity inducement. This is a standard compensation practice for talent acquisition and does not significantly impact the company's financial standing.…more
$12.83+0.23%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report